16791-41-6

Usage

Uses

Used in Pharmaceutical Industry:
2-Bromo-4,5-dimethoxyaniline is used as an intermediate in the synthesis of pharmaceuticals for its ability to be incorporated into the molecular structures of various drugs. Its unique properties and reactivity contribute to the development of new medications with potential therapeutic benefits.
Used in Dye and Pigment Production:
In the dye and pigment industry, 2-Bromo-4,5-dimethoxyaniline is used as an intermediate in the production of dyes and pigments. Its chemical structure allows for the creation of a wide range of colors and hues, making it a versatile component in the formulation of various colorants.
Used in Organic Synthesis:
2-Bromo-4,5-dimethoxyaniline is utilized as a key intermediate in organic synthesis, where it can be further reacted to form a variety of organic compounds. Its reactivity and functional groups make it suitable for use in numerous chemical processes, contributing to the synthesis of a broad spectrum of products.
It is crucial to handle 2-Bromo-4,5-dimethoxyaniline with care and adhere to safety guidelines due to its potential hazards and toxicity. Proper handling and storage are essential to ensure the safety of individuals involved in its production, use, and disposal.

Upstream product

• 881-70-9 3',4'-dimethoxyacetanilide 
• 145352-75-6 2-acetamido-4,5-dimethoxybenzoic acid 
• 51072-66-3 1-bromo-4,5-dimethoxy-2-nitro-benzene 
• 2859-78-1 4-Bromoveratrole 
• 6315-89-5 3,4-dimethoxyaniline 
• 5349-12-2 N-(2-bromo-4,5-dimethoxyphenyl)acetamide 

Downstream Products

• 173217-22-6 (2-Bromo-4,5-dimethoxy-phenyl)-but-3-enyl-amine 
• 37895-73-1 1,2-dibromo-4,5-dimethoxybenzene 
• 1232688-41-3 1-bromo-2-isocyanato-4,5-dimethoxybenzene 
• 1232685-95-8 (2S)-N-(2-bromo-4,5-dimethoxyphenyl)-2-(4-fluorophenyl)-4-oxo-2,3-dihydropyridine-1-carboxamide 
• 1232685-93-6 N-(2-bromo-4,5-dimethoxyphenyl)-4-oxo-2-phenyl-2,3-dihydropyridine-1-carboxamide 
• 29194-86-3 2-bromo-4,5-dimethoxy-N-(2-morpholin-4-yl-ethyl)-aniline 
• 5349-12-2 N-(2-bromo-4,5-dimethoxyphenyl)acetamide 
• 13794-72-4 3H-6,7-dimethoxyquinazolin-4-one 
• 13790-39-1 6,7-dimethoxy-4-chloroquinazoline 

Relevant academic research and scientific papers

Cobalt in N-doped carbon matrix catalyst for chemoselective hydrogenation of nitroarenes

Anilines as important intermediates for both organic synthesis and industrial manufactory are densely substituted with a variety of functional moieties, and the transformation of nitroarenes into corresponding anilines requires catalytically selective hydrogenation catalyst. Herein, we describe a simple pyrolysis strategy to prepare cobalt catalysts in nitrogen-doped carbon matrix applied in the selective hydrogenation of nitroarenes with molecular hydrogen. The Co/NC catalysts are obtained through thermal treatment of mixed precursors of cobalt phthalocyanine and melamine. The surface-modified Co particles with Co3O4 and CoNx sites are surrounded by N-doped carbon layers according to a series of structural characterization results. These Co/NC catalysts are capable of efficiently selective hydrogenation of nitrobenzene and various substituted nitroarenes into corresponding anilines under relatively mild reaction conditions. The optimal catalytic hydrogenation performance is contributed to the fast rate of H2 dissociated activation on the CoNx active sites and the facile adsorption of the reactant substances, which is verified by the isotopic H2-D2 exchange experiments, reactant adsorption and the ORR reaction tests. Furthermore, the heterogeneous Co/NC catalyst is highly stable without the Co leaching and deactivation issues during the recycling reaction runs.

Fe-Catalyzed Amination of (Hetero)Arenes with a Redox-Active Aminating Reagent under Mild Conditions

A novel and efficient Fe-catalyzed direct C?H amination (NH2) of arenes is reported using a new redox-active aminating reagent. The reaction is simple, and can be performed under air, mild, and redox-neutral conditions. This protocol has a broad substrate scope and could be used in the late-stage modification of bioactive compounds. Mechanistic studies demonstrate that a radical pathway could be involved in this transformation.

Novel Series of Dihydropyridinone P2X7 Receptor Antagonists

Identification of singleton P2X7 inhibitor 1 from HTS gave a pharmacophore that eventually turned into potential clinical candidates 17 and 19. During development, a number of issues were successfully addressed, such as metabolic stability, plasma stability, GSH adduct formation, and aniline mutagenicity. Thus, careful modification of the molecule, such as conversion of the 1,4-dihydropyridinone to the 1,2-dihydropyridinone system, proper substitution at C-5″, and in some cases addition of fluorine atoms to the aniline ring allowed for the identification of a novel class of potent P2X7 inhibitors suitable for evaluating the role of P2X7 in inflammatory, immune, neurologic, or musculoskeletal disorders.

QUINOLINONE PDE2 INHIBITORS

The present invention is directed to quinolinone compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compo

FUSED TRIAZOLE AMINES AS P2X7 MODULATORS

Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein X, Y, R1, R2, and R3 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of dise

DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS

Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with the P2X7 purinergic receptor.

DIHYDROPYRIDONE AMIDESAS P2X7 MODULATORS

Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, R1, R2, R3, R4, R5 and Ra are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with the P2X7 purinergic receptor.

Novel syntheses of tetrahydropyrroloquinolines: Applications to alkaloid synthesis

Two novel routes involving the intramolecular olefin insertion with a zirconium-benzyne complex, followed by a palladium-catalyzed aryl amination, have been developed for the synthesis of tetrahydropyrroloquinolines. In one approach, exemplified in the si